Entering text into the input field will update the search result below

Rhythm Pharmaceuticals' Imcivree wins EC approval to treat ultra-rare disease

  • Rhythm Pharmaceuticals (NASDAQ:RYTM) announces that the European Commission (EC) has granted marketing authorization to the company's weight management treatment Imcivree (setmelanotide) in the European Union (EU).
  • IMCIVREE looks to treat obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic

Recommended For You

More Trending News

About RYTM Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
RYTM--
Rhythm Pharmaceuticals, Inc.